Drugs / Asasantin ER
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02269228 | Feb → Apr 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02273492 | Aug → Oct 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Asasantin ER | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02269228 ↗ |
| Known as | Asasantin Extended Release (ER) | “Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin Extended Release (ER) 200/25 mg Capsules b.i.d. in a Randomized, Open, 2-way Cross-over Study in Healthy Subjects” NCT02273492 ↗ |